Search results for "formyl"

showing 7 items of 97 documents

ChemInform Abstract: Dinuclear Rh(II) Complexes in Styrene Hydroformylation. Enhancement of Catalytic Activity Through Orthometalation.

2010

Three dirhodium(II) compounds including orthometalated PPh3 ligands have been tested as catalytic precursors for the hydroformylation of styrene. The activities obtained and the wide range of selectivities have been compared to the same reaction performed with RhH(CO)(PPh3)3, Rh2(O2CCH3)4 and various amounts of triphenylphosphine.

chemistry.chemical_compoundchemistryPolymer chemistryOrganic chemistryGeneral MedicineTriphenylphosphineHydroformylationCatalysisStyreneChemInform
researchProduct

Type II diabetics with macrovascular complications: polymorphonuclear leukocyte (PMN) filtration, PMN membrane fluidity and cytosolic Ca2+ content af…

1998

We evaluated polymorphonuclear (PMN) filtration parameters, membrane fluidity and cytosolic Ca2+ content in 21 normal subjects and in 18 type II diabetics with macrovascular complications (MVC). Evaluations were carried out at baseline and after in vitro activation prolonged for 5 and 15 min. PMA (4-phorbol 12-myristate 13-acetate) and fMLP (N-formyl-methionyl-leucyl-phenylalanine) were used as stimulating agents. TMA-DPH (1-[4-(trimethylamino)phenyl]-6-phenyl-1,3,5-hexatriene) was used as fluorescent probe for the membrane fluidity tests and Fura 2-AM for the cytosolic Ca2+ content. A significant variation was evident in PMN filtration parameters at 5 and 15 min. No variation was present i…

medicine.medical_specialtyMembrane FluidityNeutrophilsEndocrinology Diabetes and MetabolismClinical BiochemistryFluorescence PolarizationBiochemistrylaw.inventionEndocrinologyCytosollawCell MovementInternal medicineMembrane fluiditymedicineHumansVascular DiseasesFiltrationAgedFluorescent DyesPolymorphonuclear leukocyteChemistryBiochemistry (medical)hemic and immune systemsGeneral MedicineMiddle AgedIn vitroN-Formylmethionine Leucyl-PhenylalanineCytosolEndocrinologyDiabetes Mellitus Type 2Tetradecanoylphorbol AcetateCalciumFura-2DiphenylhexatrieneHormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
researchProduct

Uneven modulation of the annexin 1 system in osteoblast-like cells by dexamethasone

2007

AbstractWe tested whether glucocorticoids modulated osteoblast expression of the annexin 1 system, including the ligand and two G-coupled receptors termed formyl-peptide receptor (FPR) and FPR-like-1 (FPRL-1). In Saos-2 cells, rapid up-regulation of FPR mRNA upon cell incubation with dexamethasone (0.01–1μM) was observed, with significant changes as early as 2h and a more marked response at 24h; annexin 1 and FPRL-1 mRNA changes were more subtle. At the protein level, dexamethasone provoked a rapid externalization of annexin 1 (maximal at 2h) followed by delayed time-dependent changes in the cell cytosol. Saos-2 cell surface expression of FPR or FPRL-1 could not be detected, even when dexam…

medicine.medical_specialtySaos-2mRNACellBiophysicsBiologyBiochemistryArticleDexamethasoneAnnexinCell Line TumorInternal medicinemedicineHumansReceptors LipoxinReceptorGlucocorticoidsMolecular BiologyDexamethasoneAnnexin A1OsteoblastsInterleukin-6FPRL-1OsteoblastCell BiologyReceptors Formyl PeptideCell biologyCytosolEndocrinologymedicine.anatomical_structureFPRAnnexin A2medicine.drugAnnexin A1Biochemical and Biophysical Research Communications
researchProduct

Bafetinib inhibits functional responses of human eosinophils in vitro

2012

Eosinophils play a prominent role in the process of allergic inflammation. Non-receptor associated Lyn tyrosine kinases generate key initial signals in eosinophils. Bafetinib, a specific Abl/Lyn tyrosine kinase inhibitor has shown a potent antiproliferative activity in leukemic cells, but its effects on eosinophils have not been reported. Therefore, we studied the effects of bafetinib on functional and mechanistic responses of isolated human eosinophils. Bafetinib was more potent than non-specific tyrosin kinase comparators genistein and tyrphostin inhibiting superoxide anion triggered by N-formyl-Met-Leu-Phe (fMLF; 100 nM) (−log IC50=7.25±0.04 M; 6.1±0.04 M; and 6.55±0.03 M, respectively).…

medicine.medical_specialtymedicine.drug_classFarmacologíaGenisteinApoptosisPharmacologyBiologyTyrosine-kinase inhibitorAllergic inflammationchemistry.chemical_compoundCell MovementSuperoxidesLYNInternal medicinemedicineHumansProtein Kinase InhibitorsPeroxidasePharmacologyKinaseEosinophil Cationic ProteinGranulocyte-Macrophage Colony-Stimulating FactorEosinophilLeukotriene C4Respiratory burstEosinophilsN-Formylmethionine Leucyl-PhenylalaninePyrimidinesmedicine.anatomical_structureEndocrinologychemistryCalciumInterleukin-5Tyrosine kinaseEuropean Journal of Pharmacology
researchProduct

Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death

2015

The immunogenicity of malignant cells has recently been acknowledged as a critical determinant of efficacy in cancer therapy. Thus, besides developing direct immunostimulatory regimens, including dendritic cell-based vaccines, checkpoint-blocking therapies, and adoptive T-cell transfer, researchers have started to focus on the overall immunobiology of neoplastic cells. It is now clear that cancer cells can succumb to some anticancer therapies by undergoing a peculiar form of cell death that is characterized by an increased immunogenic potential, owing to the emission of the so-called "damage-associated molecular patterns" (DAMPs). The emission of DAMPs and other immunostimulatory factors by…

medicine.medical_treatmentAPOPTOTIC CALRETICULIN EXPOSUREanti-tumor immunityimmunogenicityPHOTODYNAMIC THERAPY0302 clinical medicinetranslational medicineoncoimmunologyImmunology and AllergyCytotoxic T cellMedicineAnti-tumor immunity; Immunogenicity; Immunotherapy; Molecular medicine; Oncoimmunology; Patient prognosis; Translational medicine; Immunology; Immunology and Allergy0303 health sciencesanti-tumor immunity; immunogenicity; immunotherapy; molecular medicine; oncoimmunology; patient prognosis; translational medicineRIBOSOMAL-PROTEIN DIMERClassificationddc:3. Good health030220 oncology & carcinogenesisImmunogenic cell deathMolecular MedicineimmunotherapyACTIVATING POLYPEPTIDE-IIHIGH HYDROSTATIC-PRESSURElcsh:Immunologic diseases. AllergyANTICANCER IMMUNE-RESPONSESImmunology3122 Cancers610 Medicine & healthpatient prognosis03 medical and health sciencesImmune systemHUMAN TUMOR-CELLSFORMYL PEPTIDE RECEPTORS030304 developmental biologybusiness.industryTranslational medicineBiology and Life SciencesCYTOTOXIC T-LYMPHOCYTESImmunotherapyDendritic cellMolecular medicineNEGATIVE BREAST-CANCERImmunologyCancer cellmolecular dicine3111 Biomedicinebusinesslcsh:RC581-607Frontiers in Immunology
researchProduct

Designing P-Chirogenic 1,2-Diphosphinobenzenes at Both P-Centers Using P(III)-Phosphinites

2016

International audience; A new enantiodivergent synthesis of P-chirogenic 1,2-diphosphinobenzenes (DP*B) bearing the chirality on one or both phosphorus centers is reported using aryne chemistry. The principle is based on successive reactions of 1,2-dibromobenzene with sec-phosphide boranes, then DABCO to remove the borane, and finally with chlorophosphines or P(III)-chirogenic phosphinites. The efficiency of this synthesis was demonstrated by the stereoselective preparation of (S,S)-1,2-bis(o-anisylphenylphosphino)benzene. A comparison of DIPAMP and homochiral DP*B ligands in asymmetric Rh- or Pd-catalyzed reactions was reported.

phosphine-ligandsDIPAMPketonesStereochemistryBoranesDABCOBorane010402 general chemistry[ CHIM ] Chemical Sciences01 natural sciencesBiochemistryArynecatalyzed asymmetric hydrogenationchemistry.chemical_compoundfunctionalized alkenes[ CHIM.ORGA ] Chemical Sciences/Organic chemistry[CHIM]Chemical SciencesorganocatalysisPhysical and Theoretical Chemistryhydroformylation010405 organic chemistryChemistry[CHIM.ORGA]Chemical Sciences/Organic chemistryOrganic Chemistrycarbon-monoxide0104 chemical scienceshighly enantioselective hydrogenationOrganocatalysisderivativesStereoselectivityChirality (chemistry)phospholane ligands
researchProduct

CCDC 256886: Experimental Crystal Structure Determination

2005

Related Article: L.H.Uppadine, J.-P.Gisselbrecht, N.Kyritsakas, K.Nattinen, K.Rissanen, J.-M.Lehn|2005|Chem.-Eur.J.|11|2549|doi:10.1002/chem.200401224

tetrakis(mu~2~-4-(2-Pyridylacetylhydrazino)-6-(N-(6-methyl)-2-pyridylformyl-N'-methylhydrazino)-2-phenylpyrimidine)-di-iron(ii)-di-zinc(ii) bis(tetrafluoroborate) unknown solvateSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct